HOME ZACKS RESEARCH FUNDS PORTFOLIO BROKER RESEARCH MARKETS SCREENING VIDEO EDUCATION SERVICES
Earnings    EPS Surprises    Mutual Funds    Options            My Account    Help    
Quote:
Login Free Membership
Search:

RELATED LINKS
Free Membership
Premium Home
Zacks #1 Rank
Real Time Insight
Equity Research
My Portfolio
Stock Screener
Premium Screens
Mutual Funds
ETFs
RSS Feed
Profit from the Pros
Subscription Services
FTM Trader
Product Guide
Zacks Premium
Method for Trading
Chart Patterns Trader
Home Run Investor
Income Plus
Insider Trader
Options Trader
Reitmeister Trader
Reitmeister Value
Tactical Trader
Top 10 Stocks
Turnaround Trader
Whisper Trader
Research Wizard
Zacks Ultimate



Zacks Premium
Get profitable stock
picks and timely
market advice in
Zacks.com`s Free
Daily Newsletter!

Free Registration

View the Archive


GERN: GERON CP - Stock Quote Enter Ticker:
 

QuoteEstimatesCharts Company ReportsNewsFinancials
  Quote |  Detailed Quotes |  Real Time |  Options Chain |  Greeks Montage

GERON CP (NASD)
GERN 1.42 0.03 (2.16%) Vol.  369,563 16:00 ET

Zacks Rank: 2 - Buy

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.
Zacks Rank Definition Annualized Return
# 1Strong Buy26.04%
# 2Buy18.27%
# 3Hold9.49%
# 4Sell3.94%
# 5Strong Sell1.6%
S&P5009.23%
Zacks Rank Education - Learn more about the Zacks Rank
Zacks Rank Home - All Zacks Rank resources in one place
Zacks Premium - The only way to get access to the Zacks Rank


Day Low - High 1.38 - 1.44
52wk Low - High 1.35 - 4.50
Avg Volume 588,475
Industry MED-BIOMED/GENE
Market Cap 183.84 M
Div - Yield 0.00 - 0.00
PE (forward)
PEG Ratio N/A
Current Year Est. -.6
EPS Last Year -0.70
Detailed Quote


Premium Research: Stock Analysis

Zacks Rank

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.
Zacks Rank Definition Annualized Return
# 1Strong Buy26.04%
# 2Buy18.27%
# 3Hold9.49%
# 4Sell3.94%
# 5Strong Sell1.6%
S&P5009.23%
Zacks Rank Education - Learn more about the Zacks Rank
Zacks Rank Home - All Zacks Rank resources in one place
Zacks Premium - The only way to get access to the Zacks Rank


Short-Term Rating 1-3 Months
Zacks #1 Rank Strong Buys Zacks Premium
up 2 - Buy
Zacks Recommendation

Zacks Recommendations are an excellent predictor of stock price movement over a 6+ month time frame. The recommendations come from the Zacks Equity Research group which combines the Zacks Rank with the insights from their team of over 50 equity analysts. The result is superior long term stock ratings.

The Zacks Recommendations are split into 3 groups: Outperform, Neutral and Underperform. When Zacks Premium members click on the recommendation it will launch them to the Zacks Equity Research report for the stock. More on these reports below.

Difference Between Zacks Rank and Zacks Recommendation
Zacks Equity Research Home
Zacks Premium - The only way to get access to Zacks Recommendations


Long-Term Rating 6+ Months
All Outperform Rated Stocks Zacks Premium
PREMIUM
Zacks Industry Rank

Which industries are set to outperform or underperform the market? You'll find the answer here. We have broken down all industries into over 200 classifications. Then ranked these industries using the most powerful indicator we know (the Zacks Rank). The higher the industry rank, the better the industry should perform in the future. Once you have found an attractive industry then check out the Rank in Industry to find the best stocks within the industry.

When Zacks Premium members click on the Zacks Industry Rank link they will see the full listing of industries and their current rankings.

About Zacks Industry Rank
Zacks Industry Rank - All current industry ranks.
Zacks Premium - The only way to get access to the Zacks Industry Rank

PREMIUM
Target Price

The Zacks Price Target provides you our expectation for a stocks share price in the next 6 months. These price targets are created by the Zacks Equity Research group to coincide with their recommendations that are also based on a 6 month time horizon.

Zacks Equity Research Home
Zacks Premium - The only way to get access to the Zacks Price Targets

PREMIUM
Equity Research Report

The Zacks Recommendations and Zacks Target Prices are just two of the valuable resources you'll find in the reports created by the Zacks Equity Research group. When Zacks Premium members click on this link they will taken to a page that gives them access to the Zacks Equity Research report for the stock.

Zacks Equity Research Home Zacks Premium - The only way to get access to Zacks Recommendations


Updated as of 05/04/2012
PREMIUM
Get all our stock ratings and recommendations with a Free Trial to Zacks Premium

Premium Research: Industry Analysis

Top Peers Ticker Zacks Rank
GERON CP GERN 2
AFFYMAX INC AFFY 1
AGENUS INC AGEN 1
HESKA CORP HSKA 1
Top Peer Analysis Zacks Premium
See all MED-BIOMED/GENE Peers

BROKERAGE RECOMMENDATIONS
Current ABR 2.33
ABR (Last Week) 2.33
# of Recs in ABR 3
Average Target Price 4.50
Rank in Industry 139 out of 176
More Brokerage Recommendations


NYSE data is at least 20 minutes delayed.
NASDAQ data is at least 15 minutes delayed.

 Interactive Java Charting
 NEW!   Fundamental Charts




Zacks Community PeopleAndPicks.com
Community Rating

PeopleAndPicks.com Community Stock Ratings

Rating Recommendation % of Stocks
5 stars Strong Buy 10%
4 stars Buy 20%
3 stars Hold 40%
2 stars Sell 20%
1 stars Strong Sell 10%
0 stars Not Rated  

We believe that a community of investors working together can create a superior stock rating system. Some call this "collective intelligence". Or simply...together we can beat the market!

A stock's Community Rating is calculated based on the aggregate input of the PeopleAndPicks Community. The proportion of buy to sell ratings, recency of analysis, and the average score of the users who rate it favorably all factor into a score of one to five stars.


How do you rate GERN?

Buy Sell
Find out what the Zacks Community
thinks of GERN at PeopleAndPicks.com
 
ZACKS COMMENTARY FOR GERN
Zacks Equity Research: Report for GERN
May 04, 2012
Zacks Blog: Geron Narrows Loss on Lower Costs
May 03, 2012
Zacks Blog: Neutral on Geron Corp.
Apr 02, 2012
Zacks Blog: Geron Misses Estimates
Mar 09, 2012
Zacks Blog: Narrower Loss at Geron
Nov 07, 2011
Zacks Blog: Geron Loss In-Line with Estimates
Aug 02, 2011
Zacks Blog: Analyst Interview - International Stem Cell
Jul 27, 2011
Zacks Blog: Analyst Interview - International Stem Cell
Jul 27, 2011
More Zacks Commentary
NEWS
22 Biopharma Stocks With Breakout Potential in 2012 - TheStreet.com
May 22, 2012
Geron completes enrollment in Phase II non-small cell lung cancer trial
May 16, 2012
Geron completes enrollment in Phase II non-small cell lung cancer trial - Story Title - Comtex
May 16, 2012
Geron Q1 net loss decreases
May 14, 2012
Geron Q1 net loss decreases - Story Title - Comtex
May 14, 2012
Geron Corp. Reports Operating Results (10-Q) - GuruFocus
May 08, 2012
Geron Corporation (GERN) Corporate Event Announcement Notice
May 03, 2012
Geron Completes Enrollment in Phase 2 Clinical Trial of Imetelstat in Non-Small Cell Lung Cancer
May 03, 2012
More News
EARNINGS ESTIMATES
  This Quarter
06/2012
Next Quarter
09/2012
This Year
12/2012
Next Year
12/2013
Average Estimate -0.15 -0.15 -0.60 -0.65
Number of Estimates 3 3 3 3
Low Estimates -0.16 -0.16 -0.64 -0.72
High Estimate -0.13 -0.13 -0.51 -0.58
Year Ago EPS -0.17 -0.16 -0.74 -0.60
EPS Growth 13.73% 8.33% 19.37% -8.94%

More Estimates

COMPANY DESCRIPTION
Geron Corporation is a scientific research company that is developing techniques for the health services industry. Their research is currently divided in three different areas. First, they are looking into telomeres and telomerase and their roles in cellular aging and cancer. Second, they are looking pluripotent stem cells as a potential source for the manufacturing of replacement cells and tissues. Lastly, the company is researching nuclear transfer as a potential mechanism for generating genetically matched cells and tissues.

Full Company Report
FINANCIALS
EPS TTM -.7
Sales 2.44
Net Income -91.2
Price/Earnings N/A
Price/Book 1.4
Price/Cash Flow N/A
Price/Sales 84.06


More Financials

 
About Zacks | Advertise | Affiliate | Media | Careers | Contact Us | Help
Disclaimer | Privacy Policy | Sitemap
NYSE and AMEX data is at least 20 minutes delayed.  NASDAQ data is at least 15 minutes delayed.
Copyright 2012 Zacks Investment Research